Serum Cystatin C Is a Determinant of Paraoxonase Activity in Hemodialyzed and Renal Transplanted Patients

Background: Human paraoxonase-1 (PON1) inhibits LDL-oxidation and atherogenesis, and possesses lactonase activity. Decreased PON1 activity was found in hemodialyzed and renal transplanted patients. Cystatin C plays a protective role in atherosclerosis, and is a new, sensitive marker of renal function. The relationship between these two markers in renal failure has not been investigated. Aims: The goal of this study was to clarify the relationship between PON1 activity, cystatin C and homocysteine in chronic renal failure. We also determined the levels of oxidatively modified LDL (oxLDL) and thiobarbituric acid reactive substances (TBARS) to characterize lipid peroxidation. Patients and methods: 74 hemodialized (HD), 171 renal transplanted patients (TRX), and 110 healthy controls (C) were involved in the study. PON1 activity and TBARS levels were measured spectrophotometrically. OxLDL level was determined with sandwich ELISA. Results: There was a negative correlation between PON1 activity and cystatin C level. Homocysteine level correlated negatively with PON1 activity, and positively with cystatin C level. OxLDL and TBARS levels were significantly higher in the HD and TRX groups compared to C. Conclusions: Cystatin C may be a good predictive factor not only for homocysteine levels but for the antioxidant status in patients with renal failure and renal transplantation.

[1]  H. Sinzinger,et al.  [Hyperhomocysteinemia]. , 2020, VASA. Zeitschrift fur Gefasskrankheiten.

[2]  R. Ekart,et al.  Serum Cystatin C as an Endogenous Marker of Renal Function in Patients with Chronic Kidney Disease , 2008, Renal failure.

[3]  H. Jakubowski.  The molecular basis of homocysteine thiolactone-mediated vascular disease , 2007, Clinical chemistry and laboratory medicine.

[4]  S. Ljungman,et al.  Glomerular filtration rate as measured by serum cystatin C is an important determinant of plasma homocysteine and serum methylmalonic acid in the elderly , 2007, Journal of internal medicine.

[5]  L. Stevens,et al.  Serum cystatin C as a marker of glomerular filtration rate , 2006, Current opinion in nephrology and hypertension.

[6]  F. Trivin,et al.  Hyperhomocysteinemia, paraoxonase activity and risk of coronary artery disease. , 2006, Clinical biochemistry.

[7]  R. Bökenkamp,et al.  Cystatin C, kidney function and cardiovascular disease , 2006, Pediatric Nephrology.

[8]  H. Jakubowski.  Pathophysiological consequences of homocysteine excess. , 2006, The Journal of nutrition.

[9]  J. Joven,et al.  Influence of PON1 polymorphisms on the association between serum paraoxonase 1 and homocysteinemia in a general population. , 2006, Clinical chemistry.

[10]  J. Nilsson,et al.  Lack of the Cysteine Protease Inhibitor Cystatin C Promotes Atherosclerosis in Apolipoprotein E–Deficient Mice , 2005, Arteriosclerosis, thrombosis, and vascular biology.

[11]  H. Griffiths,et al.  Downstream effects on human low density lipoprotein of homocysteine exported from endothelial cells in an in vitro system Published, JLR Papers in Press, December 1, 2004. DOI 10.1194/jlr.M400339-JLR200 , 2005, Journal of Lipid Research.

[12]  H. Jakubowski,et al.  Autoantibodies Against N-Homocysteinylated Proteins in Humans: Implications for Atherosclerosis , 2004, Stroke.

[13]  G. Werstuck,et al.  Hyperhomocysteinemia and its role in the development of atherosclerosis. , 2003, Clinical biochemistry.

[14]  S. Prichard.  Impact of dyslipidemia in end-stage renal disease. , 2003, Journal of the American Society of Nephrology : JASN.

[15]  M. Landray,et al.  Homocysteine, renal function, and risk of cardiovascular disease. , 2003, Kidney international. Supplement.

[16]  G. Ferretti,et al.  Effect of homocysteinylation on human high-density lipoproteins: a correlation with paraoxonase activity. , 2003, Metabolism: clinical and experimental.

[17]  M. Seike,et al.  Low density lipoprotein oxidized in xanthoma tissue induces the formation and infiltration of foam cells. , 2002, Journal of dermatological science.

[18]  W. Ambrosius,et al.  Genetic determinants of homocysteine thiolactonase activity in humans: implications for atherosclerosis , 2001, FEBS letters.

[19]  H. Jakubowski.  Calcium-dependent Human Serum Homocysteine Thiolactone Hydrolase , 2000, The Journal of Biological Chemistry.

[20]  G. Paragh,et al.  Serum Paraoxonase Activity Changes in Uremic and Kidney-Transplanted Patients , 1999, Nephron.

[21]  I. Rosenberg,et al.  Determinants of fasting plasma total homocysteine levels among chronic stable renal transplant recipients. , 1999, Transplantation.

[22]  R. Kiessling,et al.  Induction of heat shock protein in monocytic cells by oxidized low density lipoprotein. , 1996, Atherosclerosis.

[23]  C. Furlong,et al.  Apolipoprotein J is associated with paraoxonase in human plasma. , 1994, Biochemistry.

[24]  S. Adkins,et al.  Studies on human serum paraoxonase/arylesterase. , 1993, Chemico-biological interactions.

[25]  F. Marumo,et al.  Deranged Concentrations of Water-Soluble Vitamins in the Blood of Undialyzed and Dialyzed Patients with Chronic Renal Failure , 1986, The International journal of artificial organs.

[26]  B. La Du,et al.  The human serum paraoxonase/arylesterase polymorphism. , 1983, American journal of human genetics.

[27]  J. Bełtowski.  Protein homocysteinylation: a new mechanism of atherogenesis? , 2005, Postepy higieny i medycyny doswiadczalnej.

[28]  R. Barouki,et al.  Inverse correlation between phenylacetate hydrolase activity of the serum PON1 protein and homocysteinemia in humans , 2005, Thrombosis and Haemostasis.

[29]  H. Jakubowski,et al.  Determinants of homocysteine-thiolactonase activity of the paraoxonase-1 (PON1) protein in humans. , 2004, Cellular and molecular biology.

[30]  M. Abrahamson,et al.  Cystatins. , 2003, Biochemical Society symposium.

[31]  Akihiko Hirata,et al.  [Cystatin C]. , 2002, Nihon rinsho. Japanese journal of clinical medicine.

[32]  J. Szegedi,et al.  Homocysteine and cystatin C level changes in haemodialysed patients and connection with cerebro- and cardiovascular complications. , 2001, Acta physiologica Hungarica.

[33]  Chemico-Biological Interactions , 2022 .